跳至主要内容
临床试验/NCT00778336
NCT00778336已完成不适用

Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters

Boston Scientific Corporation0 个研究点目标入组 452 人开始时间: 2007年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
452
主要终点
Change From Baseline to Final Angiographic Results

研究概览

简要总结

This registry collects observational data about how mid-length AngioJet catheters (ie XPEEDIOR and DVX models) are used in routine clinical practice.

详细描述

The PEARL Registry collects real world data about mid-length AngioJet catheters to:

  • Characterize usage patterns, treatment approaches, and targeted vessels
  • Document treatment strategies, including specific techniques and concomitant therapies
  • Collect outcome data during initial hospitalization and at a 3-month follow-up phone call or visit
  • Evaluate the frequency of specific clinical events in relation to risk factors, diagnosis, and treatments provided
  • Identify treatment strategies that may optimize procedural and clinical outcomes, to facilitate development of treatment guidelines
  • Offer sites a valuable resource for tracking usage and performance of the AngioJet System at their institution

Information collected by the PEARL Registry is intended for educational and clinical research purposes only.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient has been treated with a mid-length AngioJet catheter(defined as 90-120 cm in length)
  • Patient has provided appropriate authorization per institutional policy and procedure.

排除标准

  • 未提供

结局指标

主要结局

Change From Baseline to Final Angiographic Results

时间窗: Index Procedure ( pre-endovascular treatment and post-endovascular treatment)

From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms,each vessel was assigned a value by the treating physician: 1. complete occlusion (\> 90% occlusion); 2. substantial occlusion (50-90% occlusion OR \<50% occlusion and \>3cm in length); 3. partial occlusion (\<50% occlusion AND \<3cm in length); 4. patent (Without visable thrombus or occlusion). The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic value from the final value.

次要结局

  • Rethrombosis(3 Month Follow Up)
  • Description of Treatments by Thrombotic Condition(Index Procedure)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验